Alkermes plc - Asset Resilience Ratio
Alkermes plc (8AK) has an Asset Resilience Ratio of 3.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore investment intensity of Alkermes plc to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Alkermes plc's Asset Resilience Ratio has changed over time. See Alkermes plc (8AK) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Alkermes plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 8AK total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €160.31 Million | 3.76% |
| Total Liquid Assets | €160.31 Million | 3.76% |
Asset Resilience Insights
- Limited Liquidity: Alkermes plc maintains only 3.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Alkermes plc Industry Peers by Asset Resilience Ratio
Compare Alkermes plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Krka d. d
WAR:KRK |
Drug Manufacturers - Specialty & Generic | 11.18% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Guangdong Taienkang Pharmaceutical Co. Ltd
SHE:301263 |
Drug Manufacturers - Specialty & Generic | 6.08% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Alkermes plc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Alkermes plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.03% | €199.65 Million ≈ $233.41 Million |
€2.49 Billion ≈ $2.91 Billion |
-14.38pp |
| 2024-12-31 | 22.40% | €460.52 Million ≈ $538.40 Million |
€2.06 Billion ≈ $2.40 Billion |
+7.61pp |
| 2023-12-31 | 14.79% | €316.02 Million ≈ $369.46 Million |
€2.14 Billion ≈ $2.50 Billion |
-1.30pp |
| 2022-12-31 | 16.09% | €315.99 Million ≈ $369.43 Million |
€1.96 Billion ≈ $2.30 Billion |
+6.27pp |
| 2021-12-31 | 9.82% | €198.77 Million ≈ $232.38 Million |
€2.02 Billion ≈ $2.37 Billion |
-5.12pp |
| 2018-12-31 | 14.93% | €272.53 Million ≈ $318.62 Million |
€1.83 Billion ≈ $2.13 Billion |
+1.46pp |
| 2017-12-31 | 13.48% | €242.21 Million ≈ $283.17 Million |
€1.80 Billion ≈ $2.10 Billion |
-4.53pp |
| 2016-12-31 | 18.01% | €310.86 Million ≈ $363.42 Million |
€1.73 Billion ≈ $2.02 Billion |
-1.05pp |
| 2015-12-31 | 19.06% | €353.67 Million ≈ $413.48 Million |
€1.86 Billion ≈ $2.17 Billion |
-2.16pp |
| 2014-12-31 | 21.21% | €407.10 Million ≈ $475.95 Million |
€1.92 Billion ≈ $2.24 Billion |
+8.87pp |
| 2013-12-31 | 12.34% | €194.67 Million ≈ $227.59 Million |
€1.58 Billion ≈ $1.84 Billion |
-- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more